• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

黑色素瘤 III 期多中心选择性淋巴结清扫试验（MSLT-I 和 MSLT-II）的概述和更新。

Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma.

机构信息

John Wayne Cancer Institute, 2200 Santa Monica Blvd., Santa Monica, CA 90404, USA.

出版信息

Clin Exp Metastasis. 2012 Oct;29(7):699-706. doi: 10.1007/s10585-012-9503-3. Epub 2012 Jun 24.

DOI:10.1007/s10585-012-9503-3
PMID:22729520
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3463679/
Abstract

This short review offers an update on the first and second Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) for patients with melanoma, and briefly traces the development of intraoperative lymphatic mapping and sentinel node biopsy.

摘要

这篇简短的综述介绍了黑色素瘤患者的第一和第二多中心选择性淋巴结切除术试验（MSLT-I 和 MSLT-II）的最新进展，并简要追溯了术中淋巴作图和前哨淋巴结活检的发展历程。

相似文献

1
Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma.黑色素瘤 III 期多中心选择性淋巴结清扫试验（MSLT-I 和 MSLT-II）的概述和更新。
Clin Exp Metastasis. 2012 Oct;29(7):699-706. doi: 10.1007/s10585-012-9503-3. Epub 2012 Jun 24.
2
Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group.早期黑色素瘤术中淋巴管造影和前哨淋巴结切除准确性的验证：一项多中心试验。多中心选择性淋巴结切除试验组。
Ann Surg. 1999 Oct;230(4):453-63; discussion 463-5. doi: 10.1097/00000658-199910000-00001.
3
How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)?我们应如何看待多中心选择性淋巴结清扫试验-1（MSLT-1）的结果？
Ann Surg Oncol. 2008 Mar;15(3):670-3. doi: 10.1245/s10434-008-9828-y. Epub 2008 Jan 29.
4
Lymphatic mapping and sentinel lymphadenectomy in primary cutaneous melanoma.原发性皮肤黑色素瘤的淋巴绘图与前哨淋巴结切除术
Expert Rev Anticancer Ther. 2006 Jul;6(7):1105-10. doi: 10.1586/14737140.6.7.1105.
5
New Zealand patients have a higher melanoma burden in sentinel nodes and completion lymphadenectomy than patients in MSLT-II.新西兰患者在前哨淋巴结和完成淋巴结清扫术中的黑色素瘤负担高于 MSLT-II 中的患者。
J Plast Reconstr Aesthet Surg. 2023 Aug;83:98-105. doi: 10.1016/j.bjps.2023.04.019. Epub 2023 Apr 17.
6
Pathobiology of the sentinel node.前哨淋巴结的病理生物学
Curr Opin Oncol. 2008 Mar;20(2):190-5. doi: 10.1097/CCO.0b013e3282f46d70.
7
Implications of the MSLT-1 for sentinel lymph node biopsy in cutaneous head and neck melanoma.MSLT-1对皮肤头颈黑色素瘤前哨淋巴结活检的意义。
Oral Oncol. 2015 Jul;51(7):629-33. doi: 10.1016/j.oraloncology.2015.04.013. Epub 2015 Apr 30.
8
Concerns relating to the conduct and statistical analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in patients with melanoma.关于多中心选择性淋巴结清扫术试验（MSLT-1）在黑色素瘤患者中的实施及统计分析的相关问题。
J Plast Reconstr Aesthet Surg. 2009 Apr;62(4):442-6. doi: 10.1016/j.bjps.2009.01.027. Epub 2009 Feb 26.
9
Time for comprehensive reporting of MSLT-I.多导睡眠图分期试验-I全面报告的时间。
Lancet Oncol. 2006 Jan;7(1):9-11; author reply 11-2. doi: 10.1016/S1470-2045(05)70518-0.
10
Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma.高危黑色素瘤治疗中的淋巴绘图与前哨淋巴结活检
J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):603-10. doi: 10.1016/s0190-9622(98)70010-6.

引用本文的文献

1
The Role of Sentinel Node Biopsy in the Era of Adjuvant Therapy for Melanoma.前哨淋巴结活检在黑色素瘤辅助治疗时代的作用
Dermatol Pract Concept. 2024 Jan 1;14(1):e2024038. doi: 10.5826/dpc.1401a38.
2
The Evolution of the Sentinel Node Biopsy in Melanoma.黑色素瘤前哨淋巴结活检的发展历程
Life (Basel). 2023 Feb 10;13(2):489. doi: 10.3390/life13020489.
3
Trends in Skin Melanoma Burden: Findings From the Global Burden of Disease Study.皮肤黑色素瘤负担趋势：全球疾病负担研究结果
Eplasty. 2022 Apr 12;22:e9. eCollection 2022.
4
A population-based study of administrative data linkage to measure melanoma surgical and pathology quality.一项基于人群的研究，旨在通过行政数据链接来衡量黑色素瘤手术和病理质量。
PLoS One. 2022 Feb 18;17(2):e0263713. doi: 10.1371/journal.pone.0263713. eCollection 2022.
5
Application of an indocyanine green surgical fluorescence imaging system in sentinel lymph node biopsy of acral malignant melanoma.吲哚菁绿手术荧光成像系统在肢端恶性黑色素瘤前哨淋巴结活检中的应用
Ann Transl Med. 2021 Sep;9(18):1456. doi: 10.21037/atm-21-4366.
6
Genetic Variants in Immune Related Genes as Predictors of Responsiveness to BCG Immunotherapy in Metastatic Melanoma Patients.免疫相关基因中的遗传变异作为转移性黑色素瘤患者对卡介苗免疫治疗反应性的预测指标
Cancers (Basel). 2020 Dec 30;13(1):91. doi: 10.3390/cancers13010091.
7
Laparoscopically assisted ilio-inguinal lymph node dissection versus inguinal lymph node dissection in melanoma.腹腔镜辅助髂腹股沟淋巴结清扫术与腹股沟淋巴结清扫术治疗黑色素瘤的比较
Melanoma Manag. 2020 Jul 21;7(2):MMT42. doi: 10.2217/mmt-2019-0023.
8
Detection of Occult Metastases in Patients with T1 and T2 Stage Lower Lip Squamous Cell Carcinomas after Positive Lymphoscintigraphy.淋巴闪烁显像阳性后T1和T2期下唇鳞状细胞癌患者隐匿性转移的检测
Diagnostics (Basel). 2020 Feb 11;10(2):97. doi: 10.3390/diagnostics10020097.
9
Evaluation of Chest Radiographs and Laboratory Testing during Melanoma Staging Procedures.黑色素瘤分期过程中胸部X光片及实验室检查的评估
Am Surg. 2019 May 1;85(5):505-510.
10
Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma.Ⅰ期和Ⅱ期皮肤黑色素瘤患者淋巴和血行播散的危险因素。
JAMA Dermatol. 2019 Jun 1;155(6):679-687. doi: 10.1001/jamadermatol.2019.0069.

本文引用的文献

1
The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I).早期与延迟性完全淋巴结清扫术对黑色素瘤发病率和住院时间影响的比较：多中心选择性淋巴结清扫试验（I）的结果。
Ann Surg Oncol. 2010 Dec;17(12):3324-9. doi: 10.1245/s10434-010-1203-0. Epub 2010 Jul 8.
2
Authors' response to a letter to the editor re: Sentinel node biopsy for early-stage melanoma.作者对一封致编辑的信的回复：关于早期黑色素瘤的前哨淋巴结活检
Ann Surg. 2007 May;245(5):828-9. doi: 10.1097/01.sla.0000261157.79250.16.
3
Sentinel-node biopsy or nodal observation in melanoma.黑色素瘤的前哨淋巴结活检或淋巴结观察
N Engl J Med. 2006 Sep 28;355(13):1307-17. doi: 10.1056/NEJMoa060992.
4
Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial.前哨淋巴结活检用于早期黑色素瘤：国际多中心试验MSLT-I中的准确性和发病率
Ann Surg. 2005 Sep;242(3):302-11; discussion 311-3. doi: 10.1097/01.sla.0000181092.50141.fa.
5
Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node.基于原发性黑色素瘤和前哨淋巴结对非前哨淋巴结转移性黑色素瘤及临床结局的预测
Mod Pathol. 2004 Jul;17(7):747-55. doi: 10.1038/modpathol.3800117.
6
Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases.早期黑色素瘤的淋巴绘图与前哨淋巴结切除术：治疗效用以及淋巴结微解剖和分子分期对提高淋巴结微转移检测准确性的影响
Ann Surg. 2003 Oct;238(4):538-49; discussion 549-50. doi: 10.1097/01.sla.0000086543.45557.cb.
7
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.美国癌症联合委员会皮肤黑色素瘤分期系统的最终版本。
J Clin Oncol. 2001 Aug 15;19(16):3635-48. doi: 10.1200/JCO.2001.19.16.3635.
8
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.17600例黑色素瘤患者的预后因素分析：美国癌症联合委员会黑色素瘤分期系统的验证
J Clin Oncol. 2001 Aug 15;19(16):3622-34. doi: 10.1200/JCO.2001.19.16.3622.
9
Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial.一项多机构随机试验的长期结果，该试验比较了中等厚度黑色素瘤（1.0至4.0毫米）的预后因素和手术结果。黑色素瘤手术组间试验。
Ann Surg Oncol. 2000 Mar;7(2):87-97. doi: 10.1007/s10434-000-0087-9.
10
Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group.早期黑色素瘤术中淋巴管造影和前哨淋巴结切除准确性的验证：一项多中心试验。多中心选择性淋巴结切除试验组。
Ann Surg. 1999 Oct;230(4):453-63; discussion 463-5. doi: 10.1097/00000658-199910000-00001.